[DNA diagnosis in hematological malignancies].
The recent advances in molecular biology and gene engineering have greatly contributed to the diagnosis and treatment of hematopoietic malignancies, such as leukemia and malignant lymphoma. It is now possible to precisely determine the clonal origin of malignant cells, the subtype of leukemia or lymphoma, and the clinical prognosis in each patient. Furthermore, minimal residual malignant cells in leukemia or lymphoma patients after achieving complete remission can be detected by DNA analysis. Based on these analyses, theoretically treatment can be tailored for each patient. We discuss in the present paper the usefulness of DNA or gene analyses in the clinical laboratory for hematopoietic malignancies.
Nara
N
N
Laboratory Medicine, Tokyo Medical and Dental University.
D004247:DNA / Q000032:analysis*; D018432:Drug Resistance, Multiple / Q000235:genetics; D015321:Gene Rearrangement; D019337:Hematologic Neoplasms / Q000175:diagnosis* / Q000235:genetics; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000235:genetics
D007143:Immunoglobulin Heavy Chains; D004247:DNA